Сравнение
LL-37 vs. Triptorelin
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Исследования (прочее)
Исследования (прочее)
Номер CAS
597562-32-8
57773-63-4
Молекулярная масса
4493.33 g/mol
1311.45 g/mol
Период полувыведения
нет данных
3 h
Последовательность
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESpGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2Механизм действия
LL-37
LL-37 is a cationic, amphipathic helical peptide and the only member of the cathelicidin family in humans. It is generated by proteolytic cleavage from the C-terminal portion of the precursor protein hCAP18 (CAP-18). Mechanistically it associates with and can permeabilize microbial membranes; in addition it modulates immune cells, influences cytokine release, exerts chemotactic activity, and can bind extracellular self-DNA. Preclinical models have described both anti-inflammatory and pro-inflammatory effects, depending on concentration and tissue context.
Triptorelin
Triptorelin binds with high affinity to the GnRH receptor in the pituitary. After initial stimulation of LH and FSH secretion (flare phase, about 1-2 weeks), receptor desensitisation follows with consecutive gonadotropin suppression. This results in a reversible chemical castration: in men testosterone, in women oestrogen suppression to the postmenopausal range.
Доказательная база
Наивысшая доказательность
Исследование на людях
РКИ на людях
Исследования
4
4
из них на людях
1
4
Зафиксированные эффекты
4
3
Открытые противоречия
1
0
Задокументированные нежелательные явления
0
3
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between LL-37 and Triptorelin?
- LL-37 is classified as "Исследования (прочее)", while Triptorelin is classified as "Исследования (прочее)". LL-37: LL-37 is the only known human cathelicidin, a 37-amino-acid antimicrobial peptide generated by cleavage of the precursor protein hCAP18. In research it plays a central role in innate immune defence and wound healing, yet acts in a context-dependent manner as both anti- and pro-inflammatory and has been linked to autoimmune processes. LL-37 is not an approved drug; the evidence base is predominantly basic and preclinical. Triptorelin: Synthetic decapeptide GnRH agonist with increased affinity over native gonadotropin-releasing hormone. FDA- and EMA-approved since the 1980s for prostate cancer, endometriosis and precocious puberty. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, LL-37 or Triptorelin?
- The highest available evidence level is "Исследование на людях" for LL-37 and "РКИ на людях" for Triptorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of LL-37 and Triptorelin in Germany and the United States?
- Германия: LL-37 — Только для исследований, Triptorelin — Рецептурный. США: LL-37 — Только для исследований, Triptorelin — Рецептурный. These are factual summaries with source and review date on the individual pages.